Women and HIV clinical trials
Jordan E Lake1, Ruth K Friedman2, Cynthia B Cunha2, Sandra W Cardoso2, Valdilea G Veloso2, Judith S Currier1, Beatriz Grinsztejn2
1Division of Infectious Diseases, University of California at Los Angeles, Los Angeles, CA, USA; 2Fundação Oswaldo Cruz – Instituto de Pesquisa Clínica Evandro Chagas/IPEC, Rio de Janeiro, State of Rio de Janeiro, Brazil
Background: Fifty percent of people living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) worldwide are female. In Brazil, for example, 240, 000 women are infected with HIV, rates of infection in women have increased over the last two decades, and addressing HIV prevention and treatment for women at risk for, or living with, HIV/AIDS remains a challenge. To better address the needs of women living with HIV in Brazil, the Instituto de Pesquisa Clínica Evandro Chagas – Fundação Oswaldo Cruz (IPEC-FIOCRUZ) HIV Women’s Cohort was established in 1996 to study the natural history of women seeking HIV care. This analysis describes the characteristics of women in the cohort who participated in HIV clinical trials between 1999 and 2008.
Methods: A total of 736 Women’s Cohort participants were in active follow-up and 665 participants from the Women’s Cohort were included in univariable and multivariable analyses to determine socioeconomic and sociodemographic factors associated with women’s participation in HIV clinical trials at our site.
Results: Of the complete cohort, 23% participated in a clinical trial between January 1999 and July 2008. Odds of participation decreased for women who were younger than 35 years old, currently employed, had an HIV-positive sexual partner, and/or who reported a lifetime history of illicit drug use. Alternatively, the odds of participation increased for women who had more than 8 years of formal education, were living independently, and/or were married or cohabitating.
Conclusion: The rate of participation in HIV clinical trials by women in the IPEC-Fiocruz Cohort was similar to other published cohorts, but identification of local risk factors and barriers to participation remains important. Our analysis offers a novel description of the factors associated with participation in HIV clinical trials among women in care at IPEC-FIOCRUZ in Rio de Janeiro, Brazil.
Keywords: AIDS, Brazil, South America, clinical trial participationDownload Article [PDF] View Full Text [HTML]
The Patients Voice in HIV/AIDS Clinical Trial Participation: What motivates the willingness of HIV infected people to take part in HIV/AIDS clinical trials?
Book (LAP LAMBERT Academic Publishing)
Call to step up the pace of TB-HIV collaborative activities — Weekly Blitz
Discovery by biomedical research of new and improved interventions can get into the bucket of implementation.
With the ACTG, the AIDS Clinical Trials Group network?
Yes, it was an ACTG study -- but back then I don't even think it was called ACTG -- but it was studying AZT, the first drug, at high doses. We were taking it four times a day, 1,000 mg a day. I found out a year later that I was actually in the placebo group ... which probably saved my life, too. Because we found out later that AZT, at high doses, was actually killing people faster than not. He was on the treatment arm -- the actual, real treatment -- and I was on placebo. I really think, looking back, that's probably what made a difference between both of our survivals -- that and many …